Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective
| Autor: | Jia-Jie Shi, Wei Shi, Yu-Chi Chen, Jin-Jian Lu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment CD47 Antigen Antibodies Monoclonal Humanized Antineoplastic Agents Immunological Phagocytosis Neoplasms Internal medicine Signal-regulatory protein alpha medicine Humans Receptors Immunologic Immune Checkpoint Inhibitors Hematology biology business.industry Macrophages CD47 Anemia General Medicine Immunotherapy Aminoacyltransferases Antigens Differentiation Fusion protein Transmembrane protein Immune checkpoint Oncology Cancer research biology.protein Antibody business |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 148:1-14 |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | CD47, a transmembrane protein, acts as a "do not eat me" signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRPα) and enabling the tumor cells to escape from macrophage-mediated phagocytosis. Several clinical trials with CD47 targeting agents are underway and have achieved impressive results preliminarily. However, hematotoxicity (particularly anemia) has emerged as the most common side effect that cannot be neglected. In the development of CD47 targeting agents, various methods have been used to mitigate this toxicity. In this review, we summarized five strategies used to alleviate CD47 blockade-induced hematotoxicity, as follows: change in the mode of administration; dual targeting bispecific antibodies of CD47; CD47 antibodies/SIRPα fusion proteins with negligible red blood cell binding; anti-SIRPα antibodies; and glutaminyl-peptide cyclotransferase like inhibitors. With these strategies, the development of CD47 targeting agents can be improved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink